The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

NCT06546540 | Recruiting Phase 4

• 1 other identifier: BYSYDL2021005
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disease characterized by potentially widespread and progressive skin fibrosis and vascular abnormalities, and may involve the musculoskeletal, gastrointestinal, pulmonary, cardiac, renal, neuromuscular, and urogenital systems. At present, there is no clear and effective drug treatment for the progression of scleroderma skin lesions, and there is a lack of authoritative treatment recommendations. In recent years, research on the treatment of B cells in SSc suggests that targeted B cell therapy has certain safety and effectiveness for SSc patients. Telitacicept is a fully human fusion protein that is a fusion of TACI protein and IgG1 protein. Telitacicept can inhibit the further development and maturation of immature B cells by blocking BLyS. At the same time, Telitacicept can also inhibit the differentiation of mature B cells into plasma cells by blocking APRIL, and affect the secretion of abnormal self reactive plasma cell autoantibodies, better controlling disease activity. The effectiveness and safety of SSc treatment require further research. This study is an evaluator blind, parallel controlled clinical trial that included 20 SSc patients who still had skin progression despite conventional treatment. The patients were divided into two groups, one group included patients who did not improve with conventional treatment for skin lesions, and the other group included patients who received traditional conventional treatment. The main outcome of the study was to evaluate the efficacy and safety of Telitacicept in the treatment of progressive skin lesions in SSc, and the secondary outcome was to evaluate the impact of Telitacicept on lung function, gastrointestinal symptoms, pulmonary arterial hypertension, disease activity, and quality of life in SSc.

Conditions

Systemic Sclerosis

Outcome Measures

Primary Outcomes (2)

• Changes of mRSS in patients after 52 weeks of treatment

  The range and degree of skin thickening can be evaluated using the modified Rodnan skin score (mRSS) . The evaluator palpated 17 areas of the patient's body, and calculated the skin thickness of each area on a scale of 0-3 points, with a total score of 51 points. The skin progression was evaluated through changes in mRSS scores.

  base line and week 52

• The safety of Telitacicept

  Evaluate adverse drug reactions

  up to 52 weeks

Study Arms (2)

Telitacicept

EXPERIMENTAL

Drug: Telitacicept

Conventional

NO INTERVENTION

Interventions

Telitacicept DRUG

160mg，once weekly

Telitacicept

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with systemic sclerosis who met the ACR2013 classification criteria for systemic sclerosis and approved this trial
• Age: 18 years or older
• Lung function FVC% \> 50%
• Positive for ANA or scleroderma related autoantibodies
• Patients with disease activity after conventional treatment: new skin involvement or deterioration of two new body areas or skin thickening and deterioration after 6 months of conventional treatment (δMRSS ≥0 points)
• The dose of the following drugs was stable for at least 6 months before the first use of the study drug: mycophenolate mofetil, cyclophosphamide；First use of study drug precorticosteroids (≤10 mg prednisone/day or equivalent) for at least 30 days

You may not qualify if:

• Subjects who did not consent to participate in the clinical trial
• Subjects with mixed connective tissue disease or overlap syndrome
• Focal scleroderma
• Pregnant women, lactating women and men or women who have planned to have children in the last 12 month
• Allergic reaction: History of allergy to human derived biological products
• Participants who had participated in any clinical trial within 28 days prior to initial screening/or within a 5-fold half-life of the study compound (whichever is longer)
• Those who have received live vaccine in the last month
• B cell-targeted therapies such as rituximab, iparizumab, and beliumab were used within one year
• Tumor necrosis factor inhibitors and interleukin-receptor blockers were used within one year.
• Patients who used intravenous gamma globulin (IVIG), prednisone ≧100 mg/d for more than 14 days within one month or underwent plasma exchange surgery
• Use Chinese medicine for treatment within one month
• There is active infection (such as herpes zoster, HIV infection, active tuberculosis, etc.) during the screening period
• There are serious complications such as uncontrolled congestive heart failure, arrhythmias, severe pulmonary hypertension or hypertension, severe gastrointestinal involvement, liver function impairment, active infection, severe diabetes mellitus, atherosclerotic heart disease, malignancy, AIDS, or severe peripheral vascular disease.
• Patients with severe depression, psychosis or suicidal ideation

Sponsors & Collaborators

• Peking University Third Hospital: lead

Study Sites (1)

Peking Third Hospital

Beijing, China

RECRUITING

MeSH Terms

Conditions

Scleroderma, Systemic

Interventions

telitacicept

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Central Study Contacts

Jing Chai

CONTACT

86-010-18610089752; chaijing1008@163.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: August 4, 2024
• First Posted: August 9, 2024
• Study Start: June 8, 2024
• Primary Completion: December 10, 2025
• Study Completion: March 30, 2026
• Last Updated: August 9, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)